WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 – June 4, 2024.

马萨诸塞州沃尔瑟姆，2024年5月24日（环球通讯社）--瑞典孤儿Biovitrum AB（Sobi®）的北美分支机构Sobi North America今天宣布，将于2024年5月31日至6月4日在芝加哥举行的美国临床肿瘤学会（ASCO）年会上发表三篇摘要，重点介绍其骨髓纤维化治疗方案的数据。

Sobi’s commitment to delivering innovative treatments for people living with hematological diseases is seen in global studies spanning multiple rare disorders, including myelofibrosis. A retrospective analysis will be presented that demonstrates the efficacy of pacritinib in spleen volume reduction, symptom benefit and red blood cell transfusion response, compared with best available therapy, in patients with myelofibrosis who have both thrombocytopenia and anemia.

Sobi致力于为血液病患者提供创新的治疗方法，这在跨越多种罕见疾病（包括骨髓纤维化）的全球研究中有所体现。将进行回顾性分析，证明与最佳可用疗法相比，在患有血小板减少症和贫血的骨髓纤维化患者中，pacritinib在脾脏体积减少，症状缓解和红细胞输血反应方面的疗效。

An additional retrospective analysis will be presented that shows the substantial symptom benefit pacritinib provides compared with best available therapy or low-dose ruxolitinib, specifically in patients who required red blood cell transfusion at the time of pacritinib initiation. The number of patients experiencing treatment emergent Grade 3 anaemia was similar between pacritinib and BAT groups.

将进行另外的回顾性分析，显示与最佳可用疗法或低剂量ruxolitinib相比，pacritinib提供了实质性的症状益处，特别是在pacritinib开始时需要输注红细胞的患者中。pacritinib组和BAT组之间出现治疗紧急3级贫血的患者人数相似。

New real-world data will be presented that demonstrates treatment with pacritinib provides stability or improvement in thrombocytopenia and/or anemia in patients with myelofibrosis, regardless of baseline counts, and has favorable overall survival similar to other JAK inhibitor historical controls. Key Sobi data to be presented at ASCO 2024 MyelofibrosisVonjo(pacritinib)Impact of pacritinib on symptoms in patients with thrombocytopenia and myelofibrosis who require red blood cell transfusionPoster presentation #6577Monday, 3 June, 2024; 9:00 - 12:00 .

将提供新的现实世界数据，证明无论基线计数如何，pacritinib治疗均可稳定或改善骨髓纤维化患者的血小板减少症和/或贫血，并且具有与其他JAK抑制剂历史对照相似的良好总体存活率。将在ASCO 2024骨髓纤维化Vonjo（pacritinib）上提交的关键Sobi数据pacritinib对需要红细胞输血的血小板减少症和骨髓纤维化患者症状的影响海报展示෹2024年6月3日星期一；9： 00-12:00。